Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 12:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Completed Phase 4 Interventional Accepts healthy volunteers

Smoking Relapse Prevention in Schizophrenia

NCT00320697
Conditions
Schizophrenia, Schizoaffective Disorder, Smokers
Interventions
bupropion + nicotine patch + nicotine gum or lozenges, Placebo pill + placebo patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Major Depressive Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
Affective Neuroscience Laboratory
Other
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Completed Phase 4 Interventional Results available

Bupropion and Weight Control for Smoking Cessation - 1

NCT00006170
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Placebo, weight concerns intervention, smoking cessation intervention
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 3 Interventional

Lethargic Depression Study

NCT00064467
Conditions
Epilepsy, Major Depressive Disorder (MDD)
Interventions
Extended-release bupropion (HCl)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
24
States / cities
Beverly Hills, California • Sherman Oaks, California • Temecula, California + 21 more
Conditions
Tobacco Use Disorder
Interventions
Nicotine Patch, Sustained Release Bupropion
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 45 Years
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Varenicline and Bupropion for Smoking Cessation

NCT00935818
Conditions
Smoking
Interventions
Varenicline, placebo, bupropion SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Minneapolis, Minnesota • Rochester, Minnesota • La Crosse, Wisconsin
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Conditions
Smoking Cessation
Interventions
AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Little Rock, Arkansas • Lemon Grove, California • Pomona, California + 13 more
Conditions
Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Bupropion 150 mg XL, Placebo
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
362
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
Completed Phase 2 Interventional Accepts healthy volunteers

Maintaining Abstinence in Chronic Cigarette Smokers - 1

NCT00087880
Conditions
Tobacco Use Disorder
Interventions
Bupropion and NRT
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Smoking Lapse Behavior
Interventions
varenicline, bupropion, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more
Conditions
Binge-Eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Conditions
Obesity
Interventions
Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions
AXS-05 (dextromethorphan-bupropion), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
45
States / cities
Peoria, Arizona • Tempe, Arizona • Long Beach, California + 35 more
Conditions
Schizophrenia, Tobacco Use Disorder
Interventions
300 mg/day bupropion-sr, 0 mg/day bupropion-sr
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Providence, Rhode Island
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence, Cannabis Use Disorder
Interventions
Bupropion, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 19 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
smoking cessation intervention, bupropion hydrochloride, gene expression analysis, polymerase chain reaction, counseling intervention, educational intervention, psychosocial assessment and care
Behavioral · Drug · Genetic + 2 more
Lead sponsor
Lisa Sanderson Cox, PhD
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Conditions
Depressive Disorder
Interventions
WellbutrinXL, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Loss-of-Control Eating, Obesity/Overweight
Interventions
Naltrexone and Bupropion (NB) medication, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut